Narrow search
Showing 1 - 10 of 12
Cover Image
How relevant are social costs in economic evaluations? : the case of Alzheimer's disease
Peña-Longobardo, L. M.; Rodríguez-Sánchez, B.; … - In: The European journal of health economics : HEPAC ; … 20 (2019) 8, pp. 1207-1236
Persistent link: https://www.econbiz.de/10012221328
Cover Image
The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
Svedbom, Axel; Dalén, Johan; Ivergård, Moa; Borse, … - In: The European journal of health economics : HEPAC ; … 21 (2020) 1, pp. 45-54
Persistent link: https://www.econbiz.de/10012221637
Cover Image
Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France
Tremblay, Gabriel; Cariou, Clemence; Recher, Christian; … - In: The European journal of health economics : HEPAC ; … 21 (2020) 4, pp. 543-555
Persistent link: https://www.econbiz.de/10012421463
Cover Image
Estimating the marginal cost of a life year in Sweden's public healthcare sector
Siverskog, Jonathan; Henriksson, Martin - In: The European journal of health economics : HEPAC ; … 20 (2019) 5, pp. 751-762
Persistent link: https://www.econbiz.de/10012061272
Cover Image
A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based ec...
Achana, Felix; Petrou, Stavros; Khan, Kamran; Gaye, Amadou - In: The European journal of health economics : HEPAC ; … 19 (2018) 1, pp. 75-86
Persistent link: https://www.econbiz.de/10011945892
Cover Image
The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States : relationship to cost‑effectiveness analysis and...
Ghabri, Salah; Mauskopf, Josephine - In: The European journal of health economics : HEPAC ; … 19 (2018) 2, pp. 173-175
Persistent link: https://www.econbiz.de/10011946183
Cover Image
Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
Wilson, Michele R.; Bergman, Annika; Chevrou-Severac, Helene - In: The European journal of health economics : HEPAC ; … 19 (2018) 2, pp. 229-240
Persistent link: https://www.econbiz.de/10011946252
Cover Image
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
Meng, Yang; Hertel, Nadine; Ellis, John; Morais, Edith; … - In: The European journal of health economics : HEPAC ; … 19 (2018) 8, pp. 1163-1172
Persistent link: https://www.econbiz.de/10011948237
Cover Image
Costs and where to find them : identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy
Pöhlmann, J.; Norrbacka, K.; Boye, K. S.; Valentine, W. J. - In: The European journal of health economics : HEPAC ; … 21 (2020) 8, pp. 1179-1196
Persistent link: https://www.econbiz.de/10012490508
Cover Image
Costs and benefits of interventions aimed at major infectious disease threats : lessons from the literature
Kellerborg, Klas; Brouwer, Werner B. F.; Baal, Pieter van - In: The European journal of health economics : HEPAC ; … 21 (2020) 9, pp. 1329-1350
Persistent link: https://www.econbiz.de/10012491063